Shopping Cart 0
Cart Subtotal
USD 0

Insys Therapeutics Inc (INSY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Insys Therapeutics Inc (Insys) is a specialty pharmaceutical company, which discovers, develops and commercializes novel drug delivery systems of therapeutic compounds. The company harnesses its proprietary sublingual spray technology to develop pharmaceutical cannabinoids. Its flagship product, Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP). Its lead product candidate, Syndros (dronabinol oral solution), is intended for the treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in AIDS patients. The company offers its products to oncologists, pain specialists and supportive care centers for the potential treatment of addiction to opioids, opioid overdose and epilepsy. It has operations in the US and offers its products in international markets. Insys is headquartered in Chandler, Arizona, the US.

Insys Therapeutics Inc (INSY)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Insys Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Insys Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

INSYS Therapeutics Expands Agreement with University of California San Diego 12

Licensing Agreements 13

INSYS Therapeutics Enters into Licensing Agreement with Lunatus 13

Insys Therapeutics Enters into Licensing Agreement with Senzer 14

Insys Therapeutics Enters into Licensing Agreement with Gold Coast Therapeutics 15

Insys Therapeutics Enters into Licensing Agreement with California Pacific Medical Center Research Institute 16

Equity Offering 17

Insys Therapeutics Completes IPO For USD 36.8 Million 17

Insys Therapeutics Inc-Key Competitors 19

Insys Therapeutics Inc-Key Employees 20

Insys Therapeutics Inc-Locations And Subsidiaries 21

Head Office 21

Other Locations & Subsidiaries 21

Recent Developments 22

Financial Announcements 22

Nov 05, 2018: INSYS Therapeutics reports third quarter 2018 results 22

Aug 08, 2018: INSYS Therapeutics reports second quarter 2018 results 25

May 08, 2018: INSYS Therapeutics Reports First Quarter 2018 Results 27

Mar 08, 2018: INSYS Therapeutics Reports Fourth Quarter and Full Year 2017 Results 29

Nov 02, 2017: INSYS Therapeutics Reports Third Quarter 2017 Results 30

Aug 03, 2017: Insys Therapeutics Reports Second Quarter 2017 Results 31

May 09, 2017: Insys Therapeutics Reports First Quarter 2017 Results 32

Apr 03, 2017: Insys Therapeutics Reports Fourth Quarter and Year End 2016 Results 33

Corporate Communications 35

Oct 10, 2018: INSYS Therapeutics names new general counsel 35

Aug 09, 2018: INSYS Therapeutics appoints Elizabeth Bohlen to Board of Directors 36

Apr 02, 2018: INSYS Therapeutics Appoints Trudy Vanhove to Board of Directors 37

Feb 01, 2018: INSYS Therapeutics Appoints Vaseem Mahboob to Board of Directors 38

Oct 29, 2017: INSYS Therapeutics Announces Resignation of Patrick P. Fourteau from Board of Directors 39

Oct 29, 2017: INSYS Therapeutics Founder Dr. John N. Kapoor Steps Down from Board of Directors 40

Jul 18, 2017: Insys Therapeutics Appoints Andrew G. Long as Chief Financial Officer 41

May 16, 2017: Insys Therapeutics Announces Chief Financial Officer Transition 42

May 04, 2017: Insys Therapeutics Appoints Rohit Vishnoi to Board of Directors 43

Apr 24, 2017: Dr. Steven James Joins Insys Therapeutics as Vice President of Medical Affairs 44

Mar 27, 2017: Insys Announces Saeed Motahari to Become President and Chief Executive Officer and Member of the Board of Directors Effective April 17, 2017 45

Jan 09, 2017: Insys Therapeutics Announces Retirement of Dr. John N. Kapoor as CEO and Chairman; Appoints Dr. Santosh Vetticaden as Interim CEO and Steven Meyer as Chairman of the Board 46

Legal and Regulatory 47

Aug 22, 2018: Justice Department takes first-of-its-kind-legal action to reduce opioid over-prescription 47

May 15, 2018: INSYS Therapeutics Responds to Unsealing of Previously Filed Qui Tam Complaints and Recaps Transformation Efforts 51

Oct 29, 2017: INSYS Therapeutics to Record a Minimum Liability for Department of Justice Settlement in Q3 2017 52

Product News 53

07/31/2017: Insys Announces Availability of SYNDROS, the First and Only FDA-Approved Liquid Dronabinol, by Prescription 53

05/24/2017: Insys Therapeutics Announces FDA Final Product Label for Syndros 54

Product Approvals 55

Dec 06, 2017: FDA Accepts New Drug Application (NDA) for Buprenorphine Sublingual Spray from INSYS Therapeutics 55

Sep 29, 2017: INSYS Therapeutics Files New Drug Application (NDA) for Buprenorphine Sublingual Spray with FDA 56

Mar 23, 2017: DEA Schedules Insys Therapeutics' Syndros (dronabinol oral solution) as Schedule II Drug 57

Clinical Trials 58

Dec 07, 2017: INSYS Therapeutics Starts Proof-of-Concept Study of Epinephrine Nasal Spray for Anaphylaxis 58

Other Significant Developments 59

Jun 18, 2018: INSYS Therapeutics Provides an Update on Its Ongoing Transformation 59

Feb 09, 2018: INSYS Therapeutics Addresses Maryland Attorney General's Motion 60

Appendix 61

Methodology 61

About GlobalData 61

Contact Us 61

Disclaimer 61


List Of Figure

List of Figures

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Insys Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Insys Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Insys Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Insys Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

INSYS Therapeutics Expands Agreement with University of California San Diego 12

INSYS Therapeutics Enters into Licensing Agreement with Lunatus 13

Insys Therapeutics Enters into Licensing Agreement with Senzer 14

Insys Therapeutics Enters into Licensing Agreement with Gold Coast Therapeutics 15

Insys Therapeutics Enters into Licensing Agreement with California Pacific Medical Center Research Institute 16

Insys Therapeutics Completes IPO For USD 36.8 Million 17

Insys Therapeutics Inc, Key Competitors 19

Insys Therapeutics Inc, Key Employees 20

Insys Therapeutics Inc, Other Locations 21

Insys Therapeutics Inc, Subsidiaries 21

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Insys Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Insys Therapeutics Inc (Insys) is a specialty pharmaceutical company, which discovers, develops and commercializes novel drug delivery systems of therapeutic compounds. The company harnesses its proprietary sublingual spray technology to develop pharmaceutical cannabinoids. Its flagship product, Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP). Its lead product candidate, Syndros (dronabinol oral solution), is intended for the treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in AIDS patients. The company offers its products to oncologists, pain specialists and supportive care centers for the potential treatment of addiction to opioids, opioid overdose and epilepsy. It has operations in the US and offers its products in international markets. Insys is headquartered in Chandler, Arizona, the US.

Insys Therapeutics Inc (INSY)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Insys Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Insys Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

INSYS Therapeutics Expands Agreement with University of California San Diego 12

Licensing Agreements 13

INSYS Therapeutics Enters into Licensing Agreement with Lunatus 13

Insys Therapeutics Enters into Licensing Agreement with Senzer 14

Insys Therapeutics Enters into Licensing Agreement with Gold Coast Therapeutics 15

Insys Therapeutics Enters into Licensing Agreement with California Pacific Medical Center Research Institute 16

Equity Offering 17

Insys Therapeutics Completes IPO For USD 36.8 Million 17

Insys Therapeutics Inc-Key Competitors 19

Insys Therapeutics Inc-Key Employees 20

Insys Therapeutics Inc-Locations And Subsidiaries 21

Head Office 21

Other Locations & Subsidiaries 21

Recent Developments 22

Financial Announcements 22

Nov 05, 2018: INSYS Therapeutics reports third quarter 2018 results 22

Aug 08, 2018: INSYS Therapeutics reports second quarter 2018 results 25

May 08, 2018: INSYS Therapeutics Reports First Quarter 2018 Results 27

Mar 08, 2018: INSYS Therapeutics Reports Fourth Quarter and Full Year 2017 Results 29

Nov 02, 2017: INSYS Therapeutics Reports Third Quarter 2017 Results 30

Aug 03, 2017: Insys Therapeutics Reports Second Quarter 2017 Results 31

May 09, 2017: Insys Therapeutics Reports First Quarter 2017 Results 32

Apr 03, 2017: Insys Therapeutics Reports Fourth Quarter and Year End 2016 Results 33

Corporate Communications 35

Oct 10, 2018: INSYS Therapeutics names new general counsel 35

Aug 09, 2018: INSYS Therapeutics appoints Elizabeth Bohlen to Board of Directors 36

Apr 02, 2018: INSYS Therapeutics Appoints Trudy Vanhove to Board of Directors 37

Feb 01, 2018: INSYS Therapeutics Appoints Vaseem Mahboob to Board of Directors 38

Oct 29, 2017: INSYS Therapeutics Announces Resignation of Patrick P. Fourteau from Board of Directors 39

Oct 29, 2017: INSYS Therapeutics Founder Dr. John N. Kapoor Steps Down from Board of Directors 40

Jul 18, 2017: Insys Therapeutics Appoints Andrew G. Long as Chief Financial Officer 41

May 16, 2017: Insys Therapeutics Announces Chief Financial Officer Transition 42

May 04, 2017: Insys Therapeutics Appoints Rohit Vishnoi to Board of Directors 43

Apr 24, 2017: Dr. Steven James Joins Insys Therapeutics as Vice President of Medical Affairs 44

Mar 27, 2017: Insys Announces Saeed Motahari to Become President and Chief Executive Officer and Member of the Board of Directors Effective April 17, 2017 45

Jan 09, 2017: Insys Therapeutics Announces Retirement of Dr. John N. Kapoor as CEO and Chairman; Appoints Dr. Santosh Vetticaden as Interim CEO and Steven Meyer as Chairman of the Board 46

Legal and Regulatory 47

Aug 22, 2018: Justice Department takes first-of-its-kind-legal action to reduce opioid over-prescription 47

May 15, 2018: INSYS Therapeutics Responds to Unsealing of Previously Filed Qui Tam Complaints and Recaps Transformation Efforts 51

Oct 29, 2017: INSYS Therapeutics to Record a Minimum Liability for Department of Justice Settlement in Q3 2017 52

Product News 53

07/31/2017: Insys Announces Availability of SYNDROS, the First and Only FDA-Approved Liquid Dronabinol, by Prescription 53

05/24/2017: Insys Therapeutics Announces FDA Final Product Label for Syndros 54

Product Approvals 55

Dec 06, 2017: FDA Accepts New Drug Application (NDA) for Buprenorphine Sublingual Spray from INSYS Therapeutics 55

Sep 29, 2017: INSYS Therapeutics Files New Drug Application (NDA) for Buprenorphine Sublingual Spray with FDA 56

Mar 23, 2017: DEA Schedules Insys Therapeutics' Syndros (dronabinol oral solution) as Schedule II Drug 57

Clinical Trials 58

Dec 07, 2017: INSYS Therapeutics Starts Proof-of-Concept Study of Epinephrine Nasal Spray for Anaphylaxis 58

Other Significant Developments 59

Jun 18, 2018: INSYS Therapeutics Provides an Update on Its Ongoing Transformation 59

Feb 09, 2018: INSYS Therapeutics Addresses Maryland Attorney General's Motion 60

Appendix 61

Methodology 61

About GlobalData 61

Contact Us 61

Disclaimer 61


List Of Figure

List of Figures

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Insys Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Insys Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Insys Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Insys Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

INSYS Therapeutics Expands Agreement with University of California San Diego 12

INSYS Therapeutics Enters into Licensing Agreement with Lunatus 13

Insys Therapeutics Enters into Licensing Agreement with Senzer 14

Insys Therapeutics Enters into Licensing Agreement with Gold Coast Therapeutics 15

Insys Therapeutics Enters into Licensing Agreement with California Pacific Medical Center Research Institute 16

Insys Therapeutics Completes IPO For USD 36.8 Million 17

Insys Therapeutics Inc, Key Competitors 19

Insys Therapeutics Inc, Key Employees 20

Insys Therapeutics Inc, Other Locations 21

Insys Therapeutics Inc, Subsidiaries 21

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Insys Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.